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Dendritic cells (DC) are the most potent antigen present-
ing cells and therefore represent a promising tool for can-
cer immuno-therapy. We developed single use cell
processors, allowing generation of large numbers of clini-
cal grade monocyte-derived DC in serum free medium
containing GM-CSF and IL-13. We have previously dem-
onstrated that these DC cross present antigens to specific
CD8 T cells on MHC class I molecules in vitro. In order to
improve specific CD8 T cell responses, we tested Immuno-
potentiating Reconstituted Influenza Virosomes (IRIV) as
vehicles to deliver antigens into DC. IRIVs are spherical,
unilamellar vesicles with a mean diameter of 150 nm
derived from the envelope of the Influenza virus. IRIVs
could enter into DC via binding of hemagglutinin flu pro-
tein present at the surface of IRIV to sialic acid. It has been
shown that antigens encapsulated into IRIVs are delivered
to the cytosol and enter the MHC class I pathway inducing
a CD8 T cell immune response. In this study, we demon-
strated efficient uptake of PKH-26 labeled IRIVs by DC.
IRIVs did not affect DC viability and did not induce DC
maturation. In addition, IRIVs did not prevent maturation
induced by bacterial extract (FMKp) and IFNγ. In order to
study the capacity of IRIV associated with antigen to
present epitopes at the DC cell surface, we developed a
model antigen containing the highly immunogenic
mutated Melan-A26–35(27L) peptide encapsulated into
IRIVs
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